Generation of B-cell-based cellular vaccine for cancer in murine models

A B-cell-based cellular vaccine (B(Vax)), produced from 4-1BBL(+) B cells, can select tumor-specific B cells that, upon ex vivo culture, can generate tumor-specific antibodies and activate T cells. Here, we present a protocol to generate a B-cell-based vaccine in a CT2A orthotopic glioma murine mode...

Descripción completa

Detalles Bibliográficos
Autores principales: Hou, David, Katz, Joshua L., Lee-Chang, Catalina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10322876/
https://www.ncbi.nlm.nih.gov/pubmed/37083319
http://dx.doi.org/10.1016/j.xpro.2023.102219
Descripción
Sumario:A B-cell-based cellular vaccine (B(Vax)), produced from 4-1BBL(+) B cells, can select tumor-specific B cells that, upon ex vivo culture, can generate tumor-specific antibodies and activate T cells. Here, we present a protocol to generate a B-cell-based vaccine in a CT2A orthotopic glioma murine model. We describe steps for B(Vax) production involving glioma cell implantation, tissue harvesting, 4-1BBL(+) B cell isolation, and activation. We also describe assessing B(Vax) phenotype in vitro and in vivo functional status. For complete details on the use and execution of this protocol, please refer to Lee-Chang et al. (2021).(1)

Ejemplares similares